Tigecycline Market Analysis:highly implemented to treat a variety of bacterial infections

Tigecycline is a broader spectrum of glycylcycline type which acts as a protein synthesis inhibitor. Tigecycline antibiotic basically blocks the interaction of aminoacyl-tRNA with the A site of the ribosome by binding to the 30S ribosomal subunit of bacteria and thus exhibits bacteriostatic activity. Also, Tigecycline exhibits bactericidal activities against isolates of L. Pneumophila and S. Pneumoniae.

Tygacil coverage is primarily utilized to treat a variety of bacterial infections, thus portraying features of an antibiotic. Tigecycline is a first glycylcycline type that is administered intravenously. Tygacil dose and tygacil prescribing information varies from situation to situation depending on the patient and the intensity of the enigma. The demand and supply of the overall Tigecycline dose globally is expected to boost the sales of Tigecycline Market in the coming decade, says IndustryARC studies.

Tigecycline was discovered due to the growing rate of antibiotic resistance in a number of bacteria like Acinetobacter baumannii, Staphylococcus aureus, and E. coli. Tigecycline is a tetracycline derivative antibiotic and thus its structural modifications have extended its therapeutic activity to include Gram-negative and Gram-positive bacteria, comprising those of multi-drug resistance.

Tigecycline is recommended by the European Society of Clinical Microbiology and Infection as a potential salvage therapy for complicated and severe refractory Clostridium difficile infection. Tigecycline also finds application in treatment of immune-compromised patients or patients having cancer. Even more, Tigecycline have potential for use in acute myeloid leukemia. Tigecycline is prescribed at every 12 hours with slow intravenous infusion. Patients suffering with impaired liver function needs to be prescribed a lower dose of Tigecycline. No adjustments are needed for patients suffering with impaired kidney function.

More info @ http://industryarc.com/Report/15303/tigecycline-market.html

Geographical Outlook of the Tigecycline Market:

While APAC has been the leading region in the Tigecycline Market, this geography is also expected to continue the rule during the coming few years, according to IndustryARC market research study. On the other hand, North America and Europe regions are noted to be the healthy growth units in the global perspective.

Segmentation of the Tigecycline Market:

After studying the Tigecycline Market in-depth, IndustryARC has classified it into 3 broad types:

  1. By Applications: Skin & Soft Tissue Infections, Complicated Intra-abdominal Infections and Community-acquired Bacterial Pneumonia.
  2. By Target Bacteria Type: Gram Positive Bacteria and Gram Negative Bacteria.
  3. By Geography: North America, Europe, APAC and ROW.

Vendors Analysis of the Tigecycline Market:

IndustryARC has analyzed more than 40 players of the Tigecycline Market with respect to factors like market overview, product portfolio, financial status, past, present and future market trends. Few from the entire list being:

  • Hansoh Pharma
  • Amgen
  • Astrazeneca
  • Merck
  • HICIN Pharma
  • Abbott Laboratories

Avail Sample Brochure @ http://industryarc.com/pdfdownload.php?id=15303

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s